News: Portfolio 2006

OraQuick ADVANCE(R) to Be Centerpiece of Expanded HIV Testing in Philadelphia

Initial $1.5 Million Funding Increase Approved for the City's HIV/AIDS Programs

December 7, 2006: - BETHLEHEM, Pa.--(BUSINESS WIRE)--OraSure Technologies, Inc. (NASDAQ:OSUR), the leader in oral fluid diagnostics, announced that its OraQuick ADVANCE(R) Rapid HIV 1/2 Antibody Test will be the centerpiece of a planned initiative in the City of Philadelphia to provide oral fluid rapid HIV 1/2 testing to populations that are traditionally underserved and in many instances unable to access routine medical care. The initiative is being made possible through an initial $1.5 million in increased funding to expand local HIV/AIDS testing and treatment programs, the largest increase of its kind in the history of Pennsylvania.